| Literature DB >> 27294922 |
Maren Volmer-Thole1, Ralf Lobmann2.
Abstract
Diabetic foot ulceration is a serious complication of diabetes mellitus worldwide and the most common cause of hospitalization in diabetic patients. The etiology of diabetic foot ulcerations is complex due to their multifactorial nature; in the pathophysiology of diabetic foot ulceration polyneuropathy is important. Proper adherence to standard treatment strategies and interdisciplinary cooperation can reduce the still high rates of major amputations.Entities:
Keywords: diabetic foot; multidisciplinary team; neuropathy; wound healing
Mesh:
Year: 2016 PMID: 27294922 PMCID: PMC4926450 DOI: 10.3390/ijms17060917
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Risk factors of diabetic foot ulceration.
| The Pathophysiological Process Is a Combination of Several Causal Factors |
|---|
sensorimotor diabetic polyneuropathy patient age previous ulceration peripheral arterial occlusive disease (PAOD) structural deformities in the skeleton of the foot diabetes duration male gender late complications of type 2 diabetes |
Figure 1Advanced diabetic neuropathy—A point of no return? Modified version after: Peter Boucek [15].
Differential diagnosis of chronic peripheral neuropathy (axonal and demyelinating).
| Category | Etiology | |
|---|---|---|
| Diabetes | diabetes mellitus type 1, type 2 | |
| Alcohol | alcohol consumption | |
| Toxins | lead, mercury, arsenic, acrylamide, thallium, organic solvent | |
| Thyroid | myxoedema (hypothyroidism) | |
| Connective tissue disease | systemic lupus erythematosus, Sjögren syndrome, systemic sclerosis, vasculitis | |
| Infections | HIV, leprosy, Lyme borreliosis | |
| Systemic disease | liver failure (cirrhosis), renal failure (uraemia), acromegaly, amyloidosis, sarcoidosis | |
| Vitamin deficiency | vitamin B12 (distal sensitive deficit), pyroxidin overdose, thiamine (alcohol, malnutrition), malabsorption syndrome | |
| Paraneoplastic | lymphoma, paraproteins (combined with POEMS, CANOMAD syndromes) | |
| Hereditary | Charcot-Marie-Tooth disease, hereditary sensitive and autonomic neuropathy, family amyloid polyneuropathy, distal hereditary motoric neuropathy | |
| Spinal cord | trauma, tumour, infection | |
| Idiopathic | about 25% of patients | |
| Medication | Class | Medication |
| Chemotherapy | quinecin, bortezomib, platinum, (carboplatin, cisplatin), suramin, taxol (docetaxel, paclitaxel), vincristine | |
| Antibiotics | ethambutol, isoniazid, metronidazole, misonidazol, nitrofurantoin, dapson | |
| Anticonvulsants | Phenytoin | |
| Antiarrhythmic | Amiodarone | |
| Antirheumatics | chloroquine, gold | |
| Vitamins | pyridoxine (vitamin B6) | |
| Toxins (may be found in homeopathic medication) | lead, mercury, arsenic, acrylamide, thallium, organic solvent, organophosphates | |
Neurological Basic Assessment—Key Components for Diagnosing Sensorimotor Polyneuropathy.
| Component | Diagnostic Findings in Sensorimotor Polyneuropathy | |
|---|---|---|
| Sensation of pain | toothpick, disposable needles or neurotip Ask: is it painful? | distal symmetrical loss (e.g., sock-like) |
| Touch sensitivity | distal symmetrical loss (e.g., sock-like) | |
| Pressure and touch sensitivity Temperature sensation | 10 g monofilament at plantar side of metatarsal 1 or 2; distal plantar parts of big toe; if appropriate at the basis of metatarsal 3 and 5 | Screening positive if loss of sensitivity at one point at least distal symmetrical loss (e.g., sock-like) |
| Vibration measuring | first at metatarsophalangeal joint; if no sensation examination at more proximal point (medial malleolus) | Lower standard limit proximal to metatarsophalangeal joint |
| Muscle self-reflexes | Achilles tendon reflex, patellar reflex | symmetrical complete loss or reduction |
Modified from: Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Neuropathie bei Diabetes im Erwachsenenalter—Longversion. Version 1.2, 2011 (cited: 02.02.2015). Available from: http://www.diabetes.versorgungsleitlinien.de. Internet: http://www.versorgungsleitlinien.de, http://www.awmf-leitlinien.de.
Neuropathy Symptom Score (NSS).
| Symptoms at Foot or Lower Leg | Yes | No | Score |
|---|---|---|---|
| Burning sensation | □ 2 | □ 0 | |
| Numbness | □ 2 | □ 0 | |
| Paraesthesia | □ 2 | □ 0 | |
| Feeling of faintness | □ 1 | □ 0 | |
| Cramps | □ 1 | □ 0 | |
| Pain | □ 1 | □ 0 | □ points |
| Feet | □ 2 | ||
| Lower leg | □ 1 | ||
| Other localisation | □ 0 | □ points | |
| Present at night | □ 2 | ||
| Present day and night | □ 1 | ||
| Only present during daytime | □ 0 | □ points | |
| Provokes waking up at night | |||
| □ add 1 | |||
| Evaluation: 3–4 = mild symptoms; 5–6 = moderate symptoms; 7–10 = severe neuropathic symptoms | |||
Neuropathy Deficit Score (NDS).
| Achilles Tendon Reflex | Side | Right | Left |
|---|---|---|---|
| Reflex | Normal attenuated missing | □ 0 | □ 0 |
| □ 1 | □ 1 | ||
| □ 2 | □ 2 | ||
| Distal measurement at metatarsal 1 normal ≥5/8 attenuated (<5/8) or missing | |||
| □ 0 | □ 0 | ||
| □ 1 | □ 1 | ||
| Measurement at dorsum pedis, normal attenuation or missing | |||
| □ 0 | □ 0 | ||
| □ 1 | □ 1 | ||
| Measurement at dorsum pedis, normal attenuation or missing | Right | Left | |
| □ 0 | □ 0 | ||
| □ 1 | □ 1 | ||
| Evaluation: | |||
Figure 2Typical diabetic ulceration at stage 2 (Wagner/Amstrong classification) seen at typical predisposed location of metatarsal 1. The shape is typically circular and surrounded by a hyperkeratotic border. Modest erythema of the surrounding tissue suggests coinfection (if verified, stage 2b criteria are fulfilled).
Figure 3Pathophysiology of diabetic osteoarthropathy underlying the central role of the RANKL-OPG system in the development of destructive bone alterations. RANKL = receptor activator of nuclear factor-kappa B ligand; AGE = advanced glycation end product; CGRP = calcitonin gene-related peptide; eNOS = endothelial nitric oxide synthase; IL = interleukin; OPG = osteoprotegerin; RAGE = receptor for advanced glycation end products; TNF= tumor necrosis factor.